in RYR1 (c.14066T>A; p.IIe4689Asn), which segregated within the family. Although the phenotype of the affected siblings in this study was similar to previously described cases, the clinical features were more severely expressed. Our findings contribute to the expansion of phenotypes related to RYR1 dysfunction. Additionally, it supports a new RYR1 -related clinical presentation without musculoskeletal involvement. It is important that individuals with RYR1 mutations are considered susceptible to MH, as 70% of the MH cases are caused by mutations in the RYR1 gene.
gene (OMIM 180901) in chromosome 19q13.2. RYR1 plays an essential role in excitation contraction via its function as the principle calcium release channel in skeletal muscle, in addition to its structural role in bridging the sarcoplasmic reticulum and transverse tubule [MacLennan et al., 1989] .
The recessive and dominant mutations in RYR1 have been shown to cause a range of phenotypes from central core disease [Monnier et al., 2001 ] to King-Denborough syndrome [D'Arcy et al., 2008] and minicore/centronuclear myopathy with external ophthalmoplegia [Monnier et al., 2003; Jungbluth et al., 2005] . The RYR1 phenotype is prevalent in 6-9% of the European population, and the mutations classically manifest in children with ophthalmoplegia and severe skeletal myopathy, along with scoliosis and, subsequently, respiratory insufficiency [McCarthy et al., 2000; Jungbluth et al., 2005; Beggs and Agrawal, 2017] . Malignant hyperthermia (MH) susceptibility, a dominantly inherited severe pharmacogenetic reaction to volatile anesthetics and muscle relaxants, is an allelic condition (OMIM 145600) with many mutations identified [Klein et al., 2012] .
To date, and to the best of our knowledge, there have been 2 reports describing cases of RYR1 mutations in children with a combination of ptosis or ophthalmoplegia, scoliosis, and facial paralysis [Shaaban et al., 2013; AlBakri et al., 2015] without major muscle involvement. Both reports also describe the presence of MH or the susceptibility to MH in the presented cases. Using whole exome sequencing (WES), Shaaban et al. [2013] identified recessive missense mutations in RYR1 in affected members from 2 families. The mutations resulted in 2 homozygous RYR1 amino acid substitutions (E989G and R3772W) identified in 5 affected individuals from 2 consanguineous families, and 2 compound heterozygous RYR1 substitutions (H283R and R3772W) were identified in a nonconsanguineous family with 2 affected children [Shaaban et al., 2013] . Clinically, the affected individuals were reported to have marked hypoplasia of extraocular muscles and cranial nerves II, III, IV, and VI. The affected individuals in this report had both ophthalmoplegia and ptosis, but no scoliosis [Shaaban et al., 2013] . The second report by AlBakri et al. [2015] described recessive RYR1 mutations (c.6617C>T; p.T2206M) in 2 out of 4 siblings. Both cases had congenital ptosis and scoliosis, but no ophthalmoplegia. There were also no other dysmorphic features or developmental abnormalities reported.
Here, we report a consanguineous family with 2 siblings carrying a homozygous novel variant in RYR1 (c.14066T>A; p.IIe4689Asn). Both siblings presented with severe congenital ptosis, ophthalmoplegia, scoliosis, and distinctive long faces. Interestingly, no muscle weakness was observed.
Materials and Methods
The affected individuals were recruited from the Narges Medical Genetics and Prenatal Diagnosis Laboratory, Ahvaz, Iran. Genomic DNA was extracted from peripheral blood leukocytes using standard methods. WES was performed on DNA from the proband (VI-2) by Macrogen, South Korea, using a SureSelect V6-Post Capture Kit (Agilent Genomics) and HiSeq 4000 sequencer (Illumina). The high-quality data were filtered for coding (nonsynonymous, splicing, or truncating) variants followed by the removal of common variants (minor allele frequency >0.001) reported in publicly available population databases and in-house exome sequencing data on 631 control subjects. Pathogenicity and potential functional effects of the selected variants were assessed using in silico mutation prediction tools (e.g., SIFT, PolyPhen-2, MutationTaster, and PredictSNP). Selected variants were reviewed for previously reported phenotypes and functional and expression data based on OMIM, Genecards, and PubMed databases. Subsequently, those variants predicted to be damaging were considered as promising candidates for validation and segregation analysis.
Results

Clinical Findings
Here, we report 2 affected siblings ( Fig. 1 A, VI-1, VI-2) born to distantly related parents in an Arabian-Iranian family. These individuals presented with severe congenital ptosis, ophthalmoplegia, scoliosis, and distinctive long faces, but without musculoskeletal involvement.
Both children underwent a general pediatric assessment and had similar clinical presentations with a difference in the onset of scoliosis; the boy also has ligamentous laxity. At infancy, the 13-year-old girl (VI-2) developed severe thoracolumbar scoliosis, whereas the 8-year-old boy (VI-1) has had scoliosis since birth ( Fig. 2 A, B) . Radiographs confirmed scoliosis in the siblings ( Fig. 2 C, D) . Both cases have severe bilateral ptosis, which was noted soon after birth ( Fig. 1 B) . Additionally, they presented with a high-arched palate with an excess of teeth in the oral cavity and distinctive facial features ( Fig. 1 B) . Neither case had facial weakness nor any other musculoskeletal abnormality noted. Upper and lower neurological examinations were unremarkable, and weakness or cerebellar signs were not detectable. Visual acuity and auditory ability were within normal limits, and cognitive development was normal for age. Both children also have no respiratory problems. There were no abnormalities of gen-italia and no skin lesions. Heart sounds were normal. Both cases had soft nontender abdomens with no organomegaly or palpable masses. Finally, neither case has been exposed to general anesthesia; hence, we are unaware if either has MH.
Genetic Findings
WES was performed on DNA from the proband (VI-2) to identify the potential candidate variant responsible for the observed phenotype in the family. The homozygous, potentially functional variants residing within the blocks of homozygosity were prioritized. These variants were screened through dbSNP137, 1000 Genome Project, Exome Sequencing Project (ESP) database, Genome Aggregation (gnomAD) database, The Greater Middle East (GME) Variome Project, and our in-house database for the frequency in human population. We excluded synonymous variants, intronic variants (>5 bp from exon boundaries), and common variants (minor allele frequency >0.001%). The filtered data narrowed down the variants to a homozygous single nucleotide change in exon 96 of RYR1 (NM_000540.2: c.14066T>A; p. IIe4689Asn) located within an ∼ 33.5-Mb region of homozygosity in chromosome 19 at 19p12q13.42 (hg19; chr19: 22,585,517-56,171,867) . The variant has not been observed in any public variant database and is a highly conserved residue. There is a large physicochemical difference between isoleucine and asparagine. The variant is predicted to be deleterious and disease causing by the in silico tools [Polyphen: probably damaging (score 1), SIFT: deleterious (score 0) and MutationTaster: disease causing ( p value 1)]. The variant was validated by Sanger sequencing using the following pair of primers (forward: ACACACAGACCCCAGCAAGATGTC; reverse: TGA-GCCACCGTGCCCGGACCGAAACC). The mutation was homozygous in the affected individuals and heterozygous in the parents, and the only healthy sibling is a carrier ( Fig. 1 A, C) . No other pathogenic or likely pathogenic variants were identified in the currently known monogenic disease-causing genes in the WES data.
Discussion
In the current study, we investigated 2 siblings presenting with severe ptosis, ophthalmoplegia, scoliosis, and distinctive long faces. Using WES, we identified a novel missense variant in the RYR1 gene. Additionally, our results demonstrate that WES is a promising diagnostic tool for such disorders. The novel homozygous variant identified in RYR1 was c.14066T>A; p.IIe4689Asn and led to the diagnosis of RYR1 -related myopathy with ophthalmoplegia.
RYR1 is a very large gene encoded by 106 exons, and because of its size, one can speculate that it may naturally accumulate variants. The variant identified in this study may be a consequence of the size of the gene; however, there is strong evidence supporting the likelihood of causality of the variant identified in this family. The reasons for this are, for example, the fact that RYR1 has a very low residual variation intolerance score [RVIS: -8.29 (0.01%)]. Additionally, the variant has a very low allele frequency in the currently available human population databases and particularly in our in-house Iranian control database. Furthermore, the segregation of the variant within the family, the large homozygous region surrounding the variant, results from computational assessment of the variant and the absence of any other putative variants in the WES data. Most importantly, the association of RYR1 with the observed phenotype, which has been reported in several cases previously, supports the probability that the variant identified is likely causative.
Although mutations in RYR1 have a broad phenotypic spectrum, the essential clinical consideration that must be made in individuals with RYR1 mutations is their increased susceptibility to MH [Rosenberg et al., 2017] . MH ensues postexposure to succinylcholine or a volatile anesthetic, either alone or in combination. Succinylcholine is a muscle relaxant which causes depolarization of the sarcoplasmic reticulum, causing a subsequent release of calcium stores, leading to contracture of skeletal muscle with subsequent glycogenolysis due to increased cellular metabolism. As a consequence of these events, there is an increase in lactate and excessive heat production [Rosenberg et al., 2017] . Some of the other life-threatening complications of MH include compartment syndrome, rhabdomyolysis, and cardiac arrhythmias with or without cardiac arrest. MH is lethal if not treated immediately with dantrolene sodium [Rosenberg et al., 2017] . Those patients with RYR1 mutations should avoid anesthesia with the aforementioned triggering agents and should instead be treated with alternative forms such as propofol, ket- amine, and benzodiazepines, with close postoperative monitoring [Grinberg et al., 1983; Wappler, 2010] . Therefore, it is important that MH is considered in patients requiring corrective surgeries for ptosis or scoliosis. Our findings contribute to the expanding phenotypes related to RYR1 mutations. Unlike the classical presentation of RYR1 mutations in which there is significant muscular involvement, in this study, we presented an additional family with a homozygous mutation in RYR1 without any muscular involvement. These patients have good muscle strength with no muscular abnormalities noted as well as no signs of hypotonia, which are also atypical of RYR1 -related pathologies. Hence, it is important to consider RYR1 -related pathologies in patients with a variable clinical presentation of ptosis, scoliosis, facial weakness, and ophthalmoplegia in the absence of significant skeletal myopathy.
